SLC11A2 and triple-negative breast carcinoma: Strikingly, these effects in LIP levels and lung metastatic overgrowth are achieved by a highly specific and targeted disruption of DMT1-dependent iron metabolism in both human and murine triple-negative breast cancer models, i.e., MDA-MB-231 and E0771, respectively.